# Supplementary Online Content

D'Angelo SP, Russell J, Lebbé C, et al. Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis. *JAMA Oncol*. Published online March 22, 2018. doi:10.1001/jamaoncol.2018.0077



This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1. JAVELIN Merkel 200 Part B Study Group**

| Principal Investigator | Site – Country | Site – Institution |
|---|---|---|
| Arance Fernandez, Ana M | Spain | Hospital Clinic i Provincial de Barcelona |
| Ascierto, Paolo | Italy | Istituto Nazionale Tumori Fondazione G.Pascale |
| Atkinson, Victoria | Australia | Princess Alexandra Hospital |
| Aubin, François | France | CHU Besançon - Hôpital Jean Minjoz |
| Bedane, Christophe | France | CHU de Limoges - Hôpital Dupuytren |
| Begbie, Stephen | Australia | Port Macquarie Base Hospital |
| Berrocal Jaime, Alfonso | Spain | Hospital General Universitario de Valencia |
| Bhatia, Shailender | United States | University of Washington - Seattle Cancer Care Alliance |
| Brownell, Isaac | United States | National Cancer Institute |
| Burgess, Melissa | United States | University of Pittsburgh |
| Buzzoni, Roberto | Italy | Fondazione IRCCS Istituto Nazionale dei Tumori |
| Capdevila Castillon, Jaume | Spain | Hospital Universitari Vall d'Hebron |
| Chiarion Sileni, Vanna | Italy | IOV - Istituto Oncologico Veneto IRCCS |
| Chmielowski, Bartosz | United States | UCLA Medical Center |
| Dalac-Rat, Sophie | France | CHU de Dijon - Hôpital du Bocage |
| D'Angelo, Sandra P | United States | Memorial Sloan Kettering Cancer Center |
| Dreno, Brigitte | France | CHU Nantes - Hôtel Dieu |
| Dutriaux, Caroline | France | Groupe Hospitalier Saint André - Hôpital Saint André |
| Ernst, Donald | Canada | London Health Sciences Centre |
| Fazio, Nicola | Italy | IEO Istituto Europeo di Oncologia |
| Ferolla, Piero | Italy | Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia |
| Fluck, Michael | Germany | Fachklinik Hornheide |
| Gambichler, Thilo | Germany | St. Josef-Hospital Universitaetsklinikum |
| Grignani, Giovanni | Italy | Fondazione del Piemonte per l'Oncologia IRCC Candiolo |
| Grob, Jean-Jacques | France | Hôpital de la Timone |
| Guminski, Alexander | Australia | Royal North Shore Hospital |
| Hamid, Omid | United States | The Angeles Clinic and Research Institute - West LA |
| Hassel, Jessica | Germany | Universitaetsklinikum Heidelberg |
| Herbst, Rudolf | Germany | Helios Klinikum Erfurt |
| Hernandez-Aya, Leonel | United States | Washington University |
| Hogg, David | Canada | Princess Margaret Hospital |

| Principal Investigator | Site – Country | Site – Institution |
|---|---|---|
| Kaehler, Katharina | Germany | Universitaetsklinikum Schleswig-Holstein |
| Kaufmann, Roland | Germany | Klinikum der Johann Wolfgang Goethe-Universitaet |
| Kiecker, Felix | Germany | Charite Universitaetsmedizin Berlin - Campus Charite Mitte |
| Kiyohara, Yoshio | Japan | Shizuoka Cancer Center |
| Lacour, Jean-Philippe | France | CHU Nice - Hopital de l Archet 2 |
| Lebbé, Céleste | France | Hôpital Saint-Louis |
| Leccia, Marie-Thérèse | France | CHU de Grenoble - Hôpital André Michallon |
| Lewis, Karl | United States | University of Colorado Health |
| Lopez Martin, Jose Antonio | Spain | Hospital Universitario 12 de Octubre |
| Maio, Michele | Italy | A.O.U. Senese Policlinico Santa Maria alle Scotte |
| Marquez Rodas, Ivan | Spain | Hospital General Universitario Gregorio Marañon |
| Mauch, Cornelia | Germany | Universitaetsklinikum Koeln |
| Meier, Friedegund | Germany | Universitaetsklinikum Carl Gustav Carus TU Dresden |
| Meyer, Nicolas | France | CHU de Toulouse - Hôpital Larrey |
| Milella, Michele | Italy | Istituto Nazionale Tumori Regina Elena IRCCS |
| Mortier, Laurent | France | Hopital Claude Huriez - CHU Lille |
| Olszanski, Anthony | United States | Fox Chase Cancer Center |
| Pinto, Carmine | Italy | Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia |
| Rabinowits, Guilherme | United States | Dana Farber Cancer Institute |
| Robert, Caroline | France | Institut Gustave Roussy |
| Russel, Jeffrey | United States | H. Lee Moffitt Cancer Center and Research Institute, Inc |
| Saiag, Philippe | France | Hôpital Ambroise Paré - Boulogne-Billancourt |
| Samimi, Mahtab | France | CHU Tours - Hôpital Trousseau |
| Sandhu, Shahneen | Australia | Peter MacCallum Cancer Centre |
| Staub, Janina | Germany | Universitaetsklinikum Hamburg-Eppendorf |
| Terheyden, Patrick | Germany | Universitaetsklinikum Schleswig Holstein - Campus Luebeck |
| Thomas, Luc | France | Centre Hospitalier Lyon Sud |
| Van Hagen, Thomas | Australia | St John of God Subiaco Hospital |
| Walker, John | Canada | Cross Cancer Institute |
| Yamazaki, Naoya | Japan | National Cancer Center Hospital |

**eTable 2. Patient Demographic and Baseline Characteristics**

| Characteristic | N = 39 |
|---|---|
| Age, No. (%) | |
| < 65 years | 8 (20.5) |
| ≥ 65 years | 31 (79.5) |
| Median (range), years | 75.0 (47-88) |
| Sex, No. (%) | |
| Male | 30 (76.9) |
| Female | 9 (23.1) |
| Race, No. (%) | |
| White | 33 (84.6) |
| Black or African American | 1 (2.6) |
| Not collected at the site | 4 (10.3) |
| Unknown | 1 (2.6) |
| Eastern Cooperative Oncology Group performance status, No. (%) | |
| 0 | 31 (79.5) |
| 1 | 8 (20.5) |
| Site of primary tumor, No. (%)[a] | |
| Skin | 39 (100.0) |
| Visceral metastases at baseline, No, (%) | |
| Present | 26 (66.7) |
| Absent | 8 (20.5) |
| Missing[b] | 5 (12.8) |
| Time from initial diagnosis to study entry, months | |
| Median | 13.0 |
| Range | 0.7-120.9 |
| Time since first metastatic disease diagnosis, months | |
| Median | 3.1 |
| Range | 0.6-27.7 |
| Prior chemotherapy, No. (%) | |
| Yes | 5 (12.8) |
| No | 34 (87.2) |
| Receiving prior chemotherapy, per disease state, No. (%) | |
| Neoadjuvant | 0 |
| Adjuvant | 3 (7.7) |
| Locally advanced | 2 (5.1) |
| Metastatic | 0 |

[a] There were no cases of unknown primary tumor.
[b] Tumor assessment per independent review committee was not available at the time of data cutoff.

**eTable 3. Incidence of Treatment-Related Adverse Events**

| Treatment-Related Adverse Event | Any Grade, n (%) | Grade ≥3, n (%) |
|---|---|---|
| Any | 28 (71.8) | 8 (20.5) |
| Fatigue | 9 (23.1) | 0 |
| Infusion-related reaction | 9 (23.1) | 1 (2.6) |
| Asthenia | 3 (7.7) | 0 |
| Lipase increased | 3 (7.7) | 1 (2.6) |
| Elevated ALT | 3 (7.7) | 1 (2.6) |
| Arthralgia | 2 (5.1) | 0 |
| Blood CPK increased | 2 (5.1) | 1 (2.6) |
| Chills | 2 (5.1) | 0 |
| Diarrhea | 2 (5.1) | 0 |
| Dry mouth | 2 (5.1) | 0 |
| Dyspnea | 2 (5.1) | 0 |
| Eosinophilia | 2 (5.1) | 0 |
| Nausea | 2 (5.1) | 0 |
| Pruritus[a] | 2 (5.1) | 0 |
| Pyrexia | 2 (5.1) | 0 |
| Rash maculo-papular[a] | 2 (5.1) | 0 |
| Weight decreased | 2 (5.1) | 0 |
| Autoimmune nephritis | 1 (2.6) | 1 (2.6) |
| Cholangitis | 1 (2.6) | 1 (2.6) |
| Elevated AST | 1 (2.6) | 1 (2.6) |
| Gait disturbance | 1 (2.6) | 1 (2.6) |
| Paraneoplastic encephalomyelitis | 1 (2.6) | 1 (2.6) |
| Polyneuropathy | 1 (2.6) | 1 (2.6) |
| Paraneoplastic syndrome | 1 (2.6) | 1 (2.6) |
| Troponin increased | 1 (2.6) | 1 (2.6) |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase.
Adverse events of any grade in at least 5% of patients or any grade 3 adverse event.
[a] One event of pruritus and 2 events of rash maculo-papular were also considered immune-related adverse events.

**eTable 4. Immune-Related Adverse Events**

| Event | CTCAE grade | Action Taken With Study Treatment | Outcome [a] | Serious Adverse Event? |
|---|---|---|---|---|
| Rash | 1 | Dose not changed | Recovered/resolved | No |
| Pruritus | 1 | Dose not changed | Not recovered/not resolved | No |
| Pruritus | 1 | Dose not changed | Recovered/resolved | No |
| Hypothyroidism | 1 | Not applicable | Recovered/resolved | No |
| Rash | 1 | Dose not changed | Not recovered/not resolved | No |
| Pruritus | 1 | Dose not changed | Recovered/resolved | No |

[a] This is an interim analysis and events may have resolved subsequent to the data cutoff.